FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025062852> ?p ?o ?g. }

• W3025062852 endingPage "313" @default.
• W3025062852 startingPage "302" @default.
• W3025062852 abstract "Novel immunotherapies and small molecular inhibitors are transforming our approach to previously treated and newly diagnosed patients across the spectrum of non-Hodgkin lymphomas (NHLs). Anti-CD19 CAR T cells are now indicated for the treatment of relapsed/refractory aggressive B-cell lymphomas after at least two previous lines of therapy in which durable remissions are achieved in approximately 40% of previously incurable patients. Second-line chemoimmunotherapy remains the standard of care at first relapse, but poor outcomes with conventional treatment in this setting creates an appealing rationale for earlier use of CAR T cells, which is currently under investigation, along with even earlier use in selected high-risk patients in the frontline setting. Other emerging immunotherapies include antibody-drug conjugates (ADCs), such as polatuzumab vedotin for multiple-relapsed diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine-rituximab. Multiple bispecific antibodies that bring malignant B cells in contact with effector T cells appear promising in early clinical trials and will likely emerge as off-the-shelf immunotherapy options. Chemotherapy-free small molecule–based regimens are increasingly available for mantle cell (MCLs) and follicular lymphomas (FLs). Bruton tyrosine kinase inhibitors (BTKi) now represent standard second-line therapy for MCL and are being investigated in combination and as initial therapy. Lenalidomide-rituximab is an active regimen in both FL and MCL and may be used in either relapsed/refractory or previously untreated disease. Three PI3K inhibitors are approved for multiple-relapsed FL and can induce durable remissions in patients with chemotherapy- and rituximab-refractory disease. Additional emerging targeted therapies include BCL2 inhibition in MCL and EZH2 inhibition in FL." @default.
• W3025062852 created "2020-05-21" @default.
• W3025062852 creator A5002103749 @default.
• W3025062852 creator A5005159945 @default.
• W3025062852 creator A5074766331 @default.
• W3025062852 date "2020-05-01" @default.
• W3025062852 modified "2023-09-26" @default.
• W3025062852 title "ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma" @default.
• W3025062852 cites W1020989877 @default.
• W3025062852 cites W1049067418 @default.
• W3025062852 cites W1829587101 @default.
• W3025062852 cites W1840766718 @default.
• W3025062852 cites W1994719395 @default.
• W3025062852 cites W2020869508 @default.
• W3025062852 cites W2029421916 @default.
• W3025062852 cites W2038023916 @default.
• W3025062852 cites W2043622833 @default.
• W3025062852 cites W2060466778 @default.
• W3025062852 cites W2062126843 @default.
• W3025062852 cites W2077320602 @default.
• W3025062852 cites W2079262921 @default.
• W3025062852 cites W2097145287 @default.
• W3025062852 cites W2098488028 @default.
• W3025062852 cites W2108131857 @default.
• W3025062852 cites W2111716055 @default.
• W3025062852 cites W2117460825 @default.
• W3025062852 cites W2127132803 @default.
• W3025062852 cites W2133345449 @default.
• W3025062852 cites W2134861285 @default.
• W3025062852 cites W2150587745 @default.
• W3025062852 cites W2154066874 @default.
• W3025062852 cites W2157749844 @default.
• W3025062852 cites W2160093471 @default.
• W3025062852 cites W2216659987 @default.
• W3025062852 cites W2236959863 @default.
• W3025062852 cites W2237195636 @default.
• W3025062852 cites W2279127916 @default.
• W3025062852 cites W2305142474 @default.
• W3025062852 cites W2313423582 @default.
• W3025062852 cites W2475270667 @default.
• W3025062852 cites W2528264979 @default.
• W3025062852 cites W2563160427 @default.
• W3025062852 cites W2565561569 @default.
• W3025062852 cites W2582696216 @default.
• W3025062852 cites W2596568008 @default.
• W3025062852 cites W2610797169 @default.
• W3025062852 cites W2612422239 @default.
• W3025062852 cites W2614435853 @default.
• W3025062852 cites W2725925241 @default.
• W3025062852 cites W2740450710 @default.
• W3025062852 cites W2742627598 @default.
• W3025062852 cites W2744261860 @default.
• W3025062852 cites W2749289906 @default.
• W3025062852 cites W2750851922 @default.
• W3025062852 cites W2753889266 @default.
• W3025062852 cites W2762226752 @default.
• W3025062852 cites W2763241460 @default.
• W3025062852 cites W2765414225 @default.
• W3025062852 cites W2774522106 @default.
• W3025062852 cites W2775670706 @default.
• W3025062852 cites W2787370436 @default.
• W3025062852 cites W2795301499 @default.
• W3025062852 cites W2803298831 @default.
• W3025062852 cites W2806493073 @default.
• W3025062852 cites W2807906520 @default.
• W3025062852 cites W2891543930 @default.
• W3025062852 cites W2892160172 @default.
• W3025062852 cites W2903062212 @default.
• W3025062852 cites W2903225254 @default.
• W3025062852 cites W2903308035 @default.
• W3025062852 cites W2912279708 @default.
• W3025062852 cites W2923453543 @default.
• W3025062852 cites W2925270992 @default.
• W3025062852 cites W2928384177 @default.
• W3025062852 cites W2945280131 @default.
• W3025062852 cites W2954954176 @default.
• W3025062852 cites W2983720849 @default.
• W3025062852 cites W2984492263 @default.
• W3025062852 cites W2984927918 @default.
• W3025062852 cites W2985964434 @default.
• W3025062852 cites W2986196170 @default.
• W3025062852 cites W2986702822 @default.
• W3025062852 cites W2987075075 @default.
• W3025062852 cites W2987145230 @default.
• W3025062852 cites W2987755656 @default.
• W3025062852 cites W2988183880 @default.
• W3025062852 cites W2989150180 @default.
• W3025062852 cites W2990166322 @default.
• W3025062852 cites W2991566266 @default.
• W3025062852 cites W2998982556 @default.
• W3025062852 cites W4233434727 @default.
• W3025062852 doi "https://doi.org/10.1200/edbk_279043" @default.
• W3025062852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32421455" @default.
• W3025062852 hasPublicationYear "2020" @default.
• W3025062852 type Work @default.
• W3025062852 sameAs 3025062852 @default.
• W3025062852 citedByCount "15" @default.
• W3025062852 countsByYear W30250628522020 @default.

• next